ASX-Dividend-Report-Banner

Manipal Hospitals successfully performs Eastern India's first AI-powered injectable wireless pacemaker insertion

December 03, 2024 11:24 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Manipal Hospitals successfully performs Eastern India's first AI-powered injectable wireless pacemaker insertion
Image source: Kalkine Media

KOLKATA, India, Dec. 3, 2024 /PRNewswire/ -- Marking a transformative milestone in cardiac care, Manipal Hospitals, one of the largest healthcare networks in India announced the successful insertion of an AI-driven, wireless injectable pacemaker. The Aveir Leadless pacemaker by Abbott, recently introduced in India, was implanted in a 65-year-old woman at Manipal Hospital, Dhakuria, making it the first center in Eastern India to perform this procedure. The device, already in use in the US and Europe, offers a safer, less invasive alternative to traditional pacemakers. The second and third procedures in the region were also conducted at Medica Superspecialty Hospital (A unit of Manipal Hospitals) and Manipal, Mukundapur.

From left to right: Dr. Soumya Kanti Dutta, Consultant Interventional Cardiologist,Dr. Dilip Kumar, Director of the Cardiac Cath Lab & Senior Consultant Interventional Cardiologist & Electrophysiologist, Dr. P.K. Hazra, Interventional Cardiologist, Dr. Sumanta Chatterjee, Consultant Cardiologist, Mr. Rajesh Pareekh, Unit Head at Manipal Hospital Dhakuria unveiling the Aveir Leadless pacemaker after becoming the first center in Eastern India to perform the surgery.
From left to right: Dr. Soumya Kanti Dutta, Consultant Interventional Cardiologist,Dr. Dilip Kumar, Director of the Cardiac Cath Lab & Senior Consultant Interventional Cardiologist & Electrophysiologist, Dr. P.K. Hazra, Interventional Cardiologist, Dr. Sumanta Chatterjee, Consultant Cardiologist, Mr. Rajesh Pareekh, Unit Head at Manipal Hospital Dhakuria unveiling the Aveir Leadless pacemaker after becoming the first center in Eastern India to perform the surgery.

The event was attended by eminent cardiologists from Manipal Hospitals, including Dr. P.K. Hazra, Interventional Cardiologist, Manipal Hospital, Dhakuria, Dr. Sumanta Chatterjee, Consultant Cardiologist, Manipal Hospital, Dhakuria, Dr. Soumya Kanti Dutta, Consultant Interventional Cardiologist, Manipal Hospital, Dhakuria, and Dr. Dilip Kumar, Director of the Cardiac Cath Lab & Senior Consultant Interventional Cardiologist & Electrophysiologist, Medica Superspecialty Hospital (An unit of Manipal Hospitals) and Mr. Rajesh Pareekh, Unit Head at Manipal Hospital Dhakuria.

Weighing just 2.4 grams, the Aveir Leadless pacemaker uses nanotechnology to stay securely in the heart and lasts 20-25 years—three times longer than traditional pacemakers. Its non-magnetic design ensures compatibility with airport scanners, MRIs, and high-voltage currents, preserving daily functionality of the patient.

Dr. P.K. Hazra, Interventional Cardiologist, Manipal Hospital, Dhakuria explained, "The non-rechargeable Aveir Leadless pacemaker offers a key advantage: it can be upgraded from a single to a dual-chamber configuration, efficiently managing the right atrium and ventricle. This pacemaker eliminates the need for invasive surgery and external wires, and features Bluetooth-enabled technology for remote monitoring and adjustments. Specialists worldwide can now montor the patient."

Dr. Dilip Kumar, Director of the Cardiac Cath Lab & Senior Consultant Interventional Cardiologist & Electrophysiologist, Medica Superspecialty Hospital (An unit of Manipal Hospitals) stated, "While wireless pacemakers are not new, the previous models couldn't pace both chambers—the atrium and the ventricles. The pacemaker reduces the risks of hematoma formation, infections, lead dislodgement, and other lead-related issues."

Dr. Soumya Kanti Dutta, Consultant Interventional Cardiologist, Manipal Hospital, Dhakuria, added, "This pacemaker is injected directly into the heart's right ventricle, eliminating the need for external wires and surgical pockets, which are the primary causes of infections in patients. This device is perfect for those with compromised immunity, skin issues, patients on dialysis or, blood thinners. The device's minimally invasive nature also makes it ideal for those concerned about scarring."

India is now the third country to adopt the USFDA and European-approved injectable pacemaker, offering a permanent solution to enhance patients' quality of life. Notably, the procedure can only be carried out by professionals with proper training and certification

About Manipal Hospitals:

As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 37 hospitals across 19 cities with 10,500+ beds and a talented pool of 5,600+ doctors and an employee strength of over 18,600. Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys.

Please visit: https://www.manipalhospitals.com/

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.